ScienceDex / Researcher record
Kenneth Schultz
- Trethera Corporation (no department on record)
From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.
FY2026 NIH rank #6,079
Start your CV
Start from a Word CV, PubMed IDs or ORCID.
- Early Career
NIH Funding · FY2026
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
Linked awards ($M)Award-linked rank
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $2,965,289 | 5 | #2,670 |
| 2025 | $5,079,216 | 6 | #1,367 |
| 2026 | $3,042,243 | 3 | #6,079 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20245 records
- FY20256 records
- FY2026 · selected3 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Publications
Loading publications…
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 77812017Search this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award records by amount
NIH award records listing Kenneth Schultz as a PI. Multi-PI records show the full award amount for context.
- 5R44CA302066-02R44Contact PIDevelopment of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors$1.2Maward amount
- 5R44AI188587-02R44Contact PIDevelopment of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus$995Kaward amount
- 5R42DK138578-03R42Contact PIDevelopment of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease$897.3Kaward amount
Award organization
Organizations that administered FY2026 awards listing Kenneth Schultz as a PI.
FY2026 award administered by Trethera Corporation (CA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardTrethera Corporation
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #2670
- 2024Entered Top 25% NationallyRanked #2670
- 2025$5M Cumulative Funding
- 2025Entered Top 10% NationallyRanked #1367
- 2026$10M Cumulative Funding